Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01305824 · ClinicalTrials.gov registry record · Phase 2
A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
A Phase 2 study, sponsored by Proteon Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT01305824 is a Phase 2 study that has completed, run by Proteon Therapeutics. The registered enrollment target is 151 participants.
The verdict
NCT01305824, a Phase 2 study, has completed, sponsored by Proteon Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if PRT-201 when applied to a limited segment of your blood vessel (about 2 inches) immediately after surgery to create an arteriovenous fistula is safe and improves the patency of your fistula. PRT-201 is a protein that has been shown to help keep vessels open ("patent") when applied to the outside surface of the blood vessels (arteries and veins) in AVF patients in a previous study.
Interventions
- DRUG Placebo
- DRUG PRT-201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01305824
The ClinicalTrials.gov registry entry for NCT01305824 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Proteon Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01305824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01305824 about?
NCT01305824 is a clinical study titled "A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease". The purpose of this study is to determine if PRT-201 when applied to a limited segment of your blood vessel (about 2 inches) immediately after surgery to create an arteriovenous fistula is safe and improves the patency of your fistula. PRT-201 is a protein that has been shown to help keep vessels op...
What is the current status of trial NCT01305824?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2011-03. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01305824?
The interventions under investigation include: Placebo (DRUG), PRT-201 (DRUG).
Who is sponsoring clinical trial NCT01305824?
This trial is sponsored by Proteon Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.